SupporTive Care At Home Research (STAHR) for patients with advanced cancer: Protocol for a cluster non-randomized controlled trial

TL;DR

This study tests a home-based supportive care program for advanced cancer patients to reduce hospitalizations and improve quality of life.

Contribution

A novel multidimensional home-based care program is evaluated in a cluster non-randomized trial for advanced cancer patients.

Findings

The program includes home visits, regular check-ups, and multidisciplinary team support.

The primary outcome is unplanned hospitalization within six months.

The study will assess quality of life, symptom control, and caregiver burden.

Abstract

Advancements in the treatment and management of patients with cancer have extended their survival period. To honor such patients’ desire to live in their own homes, home-based supportive care programs have become an important medical practice. This study aims to investigate the effects of a multidimensional and integrated home-based supportive care program on patients with advanced cancer. SupporTive Care At Home Research is a cluster non-randomized controlled trial for patients with advanced cancer. This study tests the effects of the home-based supportive care program we developed versus standard oncology care. The home-based supportive care program is based on a specialized home-based medical team approach that includes (1) initial assessment and education for patients and their family caregivers, (2) home visits by nurses, (3) biweekly regular check-ups/evaluation and management, (4) telephone communication via a daytime access line, and (5) monthly multidisciplinary team meetings. The primary outcome measure is unplanned hospitalization within 6 months following enrollment. Healthcare service use; quality of life; pain and symptom control; emotional status; satisfaction with services; end-of-life care; advance planning; family caregivers’ quality of life, care burden, and preparedness for caregiving; and medical expenses will be surveyed. We plan to recruit a total of 396 patients with advanced cancer from six institutions. Patients recruited from three institutions will constitute the intervention group, whereas those recruited from the other three institutions will comprise the control group.

Figures